Psoriasis is one of the most common autoimmune chronic inflammatory skin diseases that affects 125 million people in the world. The most important clinical manifestation of this disease is in the form of scaly erythematous patches and plaques, which mainly involve the body's exposed surfaces such as elbows and knees.
Psoriasis

HMX202202 is a novel TYK2 inhibitor for Psoriasis

Many inflammatory cytokines play a role in the pathogenesis of psoriasis, and many of these cytokines require the activation of the JAK/STAT signaling pathway to play their role. The effect of JAK family inhibitors in reducing the symptoms of psoriasis has been proven in many studies. TYK2 is a member of the JAK kinase family, which plays a role in the signaling pathway of IL-12, IL-23 and type I IFNs. Due to the importance of TYK2 in inflammatory cytokine signaling, TYK2 inhibitors have been used in several inflammatory diseases such as psoriasis, lupus, Crohn's, psoriatic arthritis, and ulcerative colitis.
HMX202202 consists of Glycine max polyflavonoid plant extract, which is widely used in the treatment of inflammatory diseases. So far, several studies have reported its high flavonoid content and chromatographic studies have isolated several flavonoids such as Daidzin and Genistin. Based on the researches, soybeans (Glycine max) have been reported as one of the richest sources of flavonoid legumes known today. with dry weight up to 3 mg/g.

HMX202202 Target

HMX202202 content